HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER) - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Pegylated Interferon Addition to Nucleos(t)ide Analogue Treatment on HBsAg Decline and Clearance: A Meta-Analysis of Individual Participant Data from Prospective Trials (PROSPER)

  • By

  • Edo J Dongelmans

  • Lesley A Patmore

  • Seng Gee Lim

  • Marc Bourliere

  • Shaowen Jiang

  • Nathalie Ganne-Carrie

  • Willem-Pieter Brouwer

  • Jordan J Feld

  • Yuxian Huang

  • Jose A Carrion

  • Teresa Broquetas

  • Qiankun Hu

  • Scott Fung

  • Fabrice Carrat

  • Fabien Zoulim

  • Bettina E Hansen

  • Qing Xie

  • Harry L A Janssen

  • Milan J Sonneveld

  • October 1, 2026

Share

  • 1

    This meta-analysis includes individual participant data from eight prospective studies evaluating peg-IFN added to NA therapy.

  • 2

    The study establishes benchmark estimates for HBsAg decline and clearance through peg-IFN add-on therapy alongside NA treatment.

  • 3

    Chronic hepatitis B affects approximately 254 million individuals globally, leading to over 1.3 million deaths annually.

  • 4

    Achieving HBsAg loss is crucial as it can mitigate liver-related risks despite viral suppression with nucleos(t)ide analogues.

  • 5

    The findings provide important reference points for designing future clinical trials aimed at achieving HBV cure.

Original Source(s)

HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)

  • by Edo J Dongelmans, Lesley A Patmore, Seng Gee Lim, Marc Bourliere, Shaowen Jiang, Nathalie Ganne-Carrie, Willem-Pieter Brouwer, Jordan J Feld, Yuxian Huang, Jose A Carrion, Teresa Broquetas, Qiankun Hu, Scott Fung, Fabrice Carrat, Fabien Zoulim, Bettina E Hansen, Qing Xie, Harry L A Janssen, Milan J Sonneveld

  • October 1, 2026

Related Content

Low Cholesterol and Liver Risk—The Mechanism Matters

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

A U-Net Transformer for magnetic resonance elastography